{"id":20424,"date":"2022-10-25T07:03:41","date_gmt":"2022-10-25T07:03:41","guid":{"rendered":"https:\/\/peymantaeidi.net\/stem-cell\/?p=20424"},"modified":"2022-10-25T07:47:08","modified_gmt":"2022-10-25T07:47:08","slug":"take-a-look-at-recent-updates-from-asx-healthtech-stocks","status":"publish","type":"post","link":"https:\/\/peymantaeidi.net\/stem-cell\/2022\/10\/25\/take-a-look-at-recent-updates-from-asx-healthtech-stocks\/","title":{"rendered":"Take a look at recent updates from ASX Healthtech stocks"},"content":{"rendered":"<p>Medical technology is a fast growing vertical in healthcare. It includes any technology-enabled <a href=\"https:\/\/kalkinemedia.com\/au\/stocks\/healthcare\/avr-amt-osl-asx-medical-device-stocks-with-best-ytd-returns\">medical devices<\/a> and services for benefit of patients and medical professionals. Robotic surgery, CRISPR diagnostics, gene therapies, and nanotechnology are some of the examples of medical technology.<\/p>\n<p><strong><em>With this backdrop, we at Kalkine Media\u00ae discuss the recent updates of some of the medical technology firms from the ASX:<br \/><img class=\"lazyload\" data-src=\"https:\/\/peymantaeidi.net\/stem-cell\/wp-content\/uploads\/2022\/10\/mceclip0_10_25_2022_03_38_59_966736.png\" src alt=\"image\" \/><br \/><\/em><\/strong><\/p>\n<p><strong>Echo IQ (ASX:EIQ)<\/strong><\/p>\n<p><a href=\"https:\/\/kalkinemedia.com\/au\/news\/stock-market\/echo-iq-asxeiq-shares-jump-on-new-clinical-study-agreement\">Echo IQ<\/a> Limited is committed towards improving diagnosis of structural heart disease by artificial intelligence-powered technology. The medical technology firm recently got selected for inclusion in the 2022 HeartX Accelerator program. HeartX is a cardiovascular-focused healthcare accelerator program that helps to expedite deployment of new cardiovascular innovations. The company has been announced as one of the only five awardees of the HeartX accelerator program.<\/p>\n<p>Participation in HeartX will offer the following benefits to Echo IQ:<\/p>\n<ul>\n<li>Guaranteed hospital pilot projects and clinical trials in the state.<\/li>\n<li>chance to speed up US commercialisation in a way that is collaborative yet cost-effective.<\/li>\n<li>Support to the company&#8217;s FDA application.<\/li>\n<li>Securing an additional equity funding of US$150,000.<\/li>\n<\/ul>\n<p>[embedded content]<\/p>\n<p><strong>Adherium Limited (ASX:ADR)<\/strong><\/p>\n<p><a href=\"https:\/\/kalkinemedia.com\/au\/companies\/healthcare\/adr-adherium-limited\">Adherium<\/a> aspires to become a leading digital health solutions provider for management of respiratory diseases. The ASX-listed international respiratory eHealth company is focused on respiratory eHealth, remote monitoring, and data management solutions.<\/p>\n<p>The company&#8217;s sensor technology and cloud-based platform, Hailie\u00ae, offers real time feedback on patients&#8217; use of inhaled medication. Its other benefits are as follows:<\/p>\n<ul>\n<li>Enables optimal management of patients with difficult-to-treat, severe asthma, and chronic obstructive pulmonary disease (COPD), and<\/li>\n<li>Reduces direct and indirect costs of healthcare.<\/li>\n<\/ul>\n<p>In the 2022 annual report, Adherium reported a nearly 32% increase in revenue from ordinary activities. The company&#8217;s CEO stated, &#8220;Adherium progressed with US FDA 510(k) clearances from covering 71% to 91% of the US top 20 branded inhaler medications by sales volume.&#8221;<\/p>\n<p><strong>4dmedical Limited (ASX:4DX)<br \/><img class=\"lazyload\" data-src=\"https:\/\/peymantaeidi.net\/stem-cell\/wp-content\/uploads\/2022\/10\/mceclip1_10_25_2022_03_39_52_141364.png\" width=\"800\" src alt=\"image\" \/><br \/><\/strong><\/p>\n<p>4DMedical Limited (ASX:<a href=\"https:\/\/kalkinemedia.com\/au\/companies\/technology\/4dx-4dmedical-limited\">4DX<\/a>) recently informed the market that American Medical Association has accepted its XV LVAS\u00ae application to establish a new Category III Current Procedural Terminology (CPT) code \u2013 Cat III code. According to the company, the said code is a key milestone for XV LVAS\u00ae to become a fully commercialised and reimbursable product in the US. Additionally, this will expand 4DMedical&#8217;s product visibility in the US market.<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Medical technology is a fast growing vertical in healthcare. It includes any technology-enabled medical devices<\/p>\n","protected":false},"author":1,"featured_media":20426,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/posts\/20424"}],"collection":[{"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/comments?post=20424"}],"version-history":[{"count":3,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/posts\/20424\/revisions"}],"predecessor-version":[{"id":20429,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/posts\/20424\/revisions\/20429"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/media\/20426"}],"wp:attachment":[{"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/media?parent=20424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/categories?post=20424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peymantaeidi.net\/stem-cell\/wp-json\/wp\/v2\/tags?post=20424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}